21012 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Blood coagulation or fibrinolysis factors Factors VIII
Modified Factor VIII
#302Compositions comprising a polymeric reagent and a pharmacologically active agent
#303Muteins of clotting factor VIII
#304Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
#305Optimised coding sequence and promoter
#306Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
#307THERAPEUTIC FACTOR VIII ANTIBODIES
#308CELL SYSTEMS AND METHODS FOR DELIVERING DISEASE-SPECIFIC THERAPIES
#309Factor VIII Conjugates
#310ALLELIC VARIANTS OF HUMAN FACTOR VIII
#311FVIII peptides for immune tolerance induction and immunodiagnostics
#312Compounds and methods for modulating pharmacokinetics
#313Albumin binding probes and drug conjugates thereof
#314Compositions and Methods of Treatment of Black Hemophiliac Patients
#315NEW PROTECTING COMPOSITIONS FOR RECOMBINANTLY PRODUCED FACTOR VII
#316Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
#317Nucleic acid molecules encoding modified factor VIII proteins
#318Conjugates of biologically active molecules to functionalized polymers
#319PRODRUGS CONTAINING ALBUMIN BINDING PROBE
#320Coagulation factor VIII with reduced immunogenicity
#321OPTIMISED SUBCUTANEOUS THERAPEUTIC AGENTS
#322Compounds Suitable for Treatment of Haemophilia
#323Pharmaceutical Composition Suitable for Treatment of Haemophilia
#324UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE
#325RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE
#326Albumin-free factor VIII formulations
#327Chimeric factor VIII polypeptides and uses thereof
#328Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
#329POLYSACCHARIDE-PROTEIN CONJUGATES REVERSIBLY COUPLED VIA IMINE BONDS
#330Compositions and methods for immune tolerance induction
#331Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
#332Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#333Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance
#334Methods comprising dosing combinations for reducing undesired humoral immune responses
#335Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
#336Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
#337Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
#338Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII
#339Factor VIII polypeptide formulations
#340Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
#341RECOMBINANT FVIII FORMULATIONS
#342Methods for treating bleeding disorders
#343METHODS OF USING ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING BLEEDING DISORDERS
#344Method for improving the stability of purified factor VIII after reconstitution
#345Conjugated factor VIII molecules
#346Pharmaceutical compositions of conjugates formed from polymer derivatives having particular atom arrangements
#347Targeted coagulation factors and method of using the same
#348Stabilizing agent for pharmaceutical proteins
#349Manufacturing and purification processes of Complex protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins
#350von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
#351Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#352Compounds suitable for treatment of haemophilia
#353Methods and compositions for treating bleeding disorders
#354MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
#355Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
#356Therapeutic factor VIII antibodies
#357Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
#358Albumin-free factor VIII formulations
#359CONJUGATED BLOOD COAGULATION FACTOR VIII
#360Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
#361Recombinant factor VIII having increased stability
#362INACTIVATION RESISTANT FACTOR VIII
#363Factor VIII Molecules With Reduced VWF Binding
#364Method for activation and conjugation of biomolecules
#365Optimised coding sequence and promoter
#366Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
#367Modified factor VIII
#368Conjugated FVIII variants
#369MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
#370Treatment of coagulation disease by administration of recombinant VWF
#371COMPOSITIONS AND METHODS OF TREATMENT OF BLACK HEMOPHILIAC PATIENTS
#372Method of administering porcine B-domainless fVIII
#373Polymer-factor VIII conjugate compositions
#374Polymer Factor VIII moiety conjugates
#375FACTOR VIII POLYMER CONJUGATES
#376Stabilization of liquid solutions of recombinant protein for frozen storage
#377Inactivation Resistant Factor VIII
#378Methods for hematopoietic precursor mobilization
#379Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate
#380Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
#381Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
#382ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS
#383FVIII peptides for immune tolerance induction and immunodiagnostics
#384PRODRUGS CONTAINING ALBUMIN BINDING PROBE
#385Methods for treating bleeding disorders using sulfated polysaccharides
#386PROTEIN CONJUGATE HAVING AN ENDOPEPTIDASE- CLEAVABLE BIOPROTECTIVE MOIETY
#387COMPOSITIONS AND METHODS FOR TREATING PLASMA PROTEIN DEFICIENCY DISORDERS
#388Albumin-free factor VIII formulations
#389Modified Blood Factors Comprising a Low Degree of Water Soluble Polymer
#390Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
#391Method of treating thrombocytopenia
#392Enhancing coagulation or reducing fibrinolysis
#393Method of producing recombinant high molecular weight vWF in cell culture
#394Method of producing recombinant ADAMTS13 in cell culture
#395Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
#396Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
#397Aldehyde tags, uses thereof in site-specific protein modification
#398FVIII Muteins for Treatment of Von Willebrand Disease
#399Treatment of bleeding with low half-life fibrinogen
#400Aldehyde tags, uses thereof in site-specific protein modification
#401Methods and compositions for treating bleeding disorders
#402Methods for treating bleeding disorders using sulfated polysaccharides
#403COAGULATION FACTOR MODULATION FOR CONTROLLING TRANSPLANT ORGAN SIZE
#404Factor VIII polymer conjugates
#405Methods for forming polymer-drug conjugates
#406NEW PROTECTING COMPOSITIONS FOR RECOMBINANTLY PRODUCED FACTOR VIII
#407PREDICTING AND REDUCING ALLOIMMUNOGENICITY OF PROTEIN THERAPEUTICS
#408Methods and compositions for treating bleeding disorders
#409Process of purifying coagulation factor VIII
#410Nanoparticles for protein drug delivery
#411Compositions of Less Immunogenic and Long-Circulating Protein-Lipid Complexes
#412Factor VIII polypeptide having factor VIII:C activity
#413Factor VIII polymer conjugates
#414Factor VIII polymer conjugates
#415Factor VIII polymer conjugates
#416von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
#417Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI
#418Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8
#419Polysaccharide-protein conjugates reversibly coupled via imine bonds
#420Targeted Coagulation Factors and Method of Using the Same
#421Blood coagulation protein conjugates
#422Stable Therapeutic Proteins
#423Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
#424Allelic Variants of Human Factor VIII
#425Suppression of immune response to factor VIII in hemophilia A patients
#426USE OF RAPAMYCIN TO INHIBIT IMMUNE RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS
#427Factor VIII polymer conjugates
#428Factor VIII polymer conjugates
#429FACTOR VIII FORMULATIONS
#430Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
#431Polymer-factor VIII moiety conjugates
#432Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
#433Polymer factor VIII moiety conjugates
#434Factor VIII compositions
#435Stabilization of liquid solutions of recombinant protein for frozen storage
#436Method Of Complexing A Protein By The Use Of A Dispersed System And Proteins Thereof
#437MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER
#438Synergistic therapeutic use of Prothrombin Complex Concentrates with FVIII concentrates
#439Factor VIII conjugates
#440MODIFIED PROTEINS
#441MODIFIED FACTOR VIII
#442Inhibition of the Anti-FVIII Immune Response
#443Methods of administering porcine B-domainless fVIII
#444Methods for treating bleeding disorders using sulfated polysaccharides
#445METHOD AND PRODUCT FOR LOCATING AN INTERNAL BLEEDING SITE
#446Use of Blood Coagulation Factor XIII for Treating Hemophilia A
#447Modified recombinant factor VIII and von Willebrand factor and methods of use
#448Stabilised compositions of factor VII polypeptides
#449USE OF FIBROUS TISSUE INDUCING PROTEINS FOR HERNIA REPAIR
#450Dried blood factor composition comprising trehalose
#451THERAPEUTIC METHOD FOR BLOOD COAGULATION DISORDER
#452Pharmaceutical Preparations And Medicines Capable Of Generating, And/Or Containing, Thrombin
#453Recombinant factor VIII having reduced inactivation by activated protein C
#454Recombinant factor VIII having increased stability
#455Factor VIII polymer conjugates
#456Reconstitution medium for protein and peptide formulations
#457Compositions and methods for less immunogenic protein-lipid complexes
#458Use of Factor VIIa for the Treatment of Burn Trauma
#459Materials and methods for the detection of nitrated fibrinogen
#460Polymer-factor VIII moiety conjugates
#461Use of Blood Coagulation Factor XIII for Treating Hemophilia A
#462Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
#463Factor IX: remodeling and glycoconjugation of factor IX
#464Single-dose administration of Factor VIIa
#465Conjugates of a Polymer and a Protein Linked by an Oxime Group
#466Aldehyde tags, uses thereof in site-specific protein modification
#467Albumin-free factor VIII formulations
#468Compositions and Methods for Producing Vascular Occlusion Using a Solid-Phase Platelet Binding Agent
#469USE OF RAPAMYCIN TO INHIBIT RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS
#470Combined Use of Factor VII Polypeptides and Factor VIII Polypeptides
#471Combined Use of Factor VII Polypeptides and Factor IX Polypeptides
#472Polymer-factor VIII moiety conjugates
#473Dried blood factor composition comprising trehalose
#474Virally-safe factor VIII with a low content of higher multimers
#475Method for treating blood coagulation disorders
#476Compositions of less immunogenic and long-circulating protein-lipid complexes
#477Compositions, Methods, and Kits for Treating Dry Eye
#478Genetic modification of the lung as a portal for gene delivery
#479Compositions and methods for locating an internal bleeding site
#480Method of administering porcine B-domainless fVIII
#481Dried blood factor composition comprising trehalose
#482Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
#483Haemostatic sprays and compositions
#484Compositions and methods for less immunogenic protein-lipid complexes
#485Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
#486Modified factor VIII
#487Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
#488Use of fibrous tissue inducing proteins for hernia repair
#489Use of blood coagulation factor XIII for treating hemophilia A
#490Stabilised compositions of Factor VII
#491Inactivation resistant factor VIII
#492Combined use of factor VII polypeptides and factor VIII polypeptides
#493Conjugates formed from polymer derivatives having particular atom arrangements
#494Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment
#495Drug for treating hemophilia and method of treating hemophilia using the same
#496Combined use of factor VII polypeptides and factor IX polypeptides
#497Albumin-free factor VIII formulations
#498Factor VIII polypeptide having factor VIII:C activity
#499Site-directed modification of FVIII
#500Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
#501Method and product for locating an internal bleeding site
#502Stable therapeutic proteins
#503Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide
#504Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent
#505Methods for treating bleeding disorders using sulfated polysaccharides
#506Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers
#507Adeno-associated vector compositions for expression of Factor VIII
#508Modified factor VIII
#509Stable pharmaceutical composition containing factor VIII
#510Nitrated fibrinogen as a marker for coronary artery disease and rapid blood clot formation
#511Factor VIII/vWF-complex and methods of purifying same
#512Compositions and methods for less immunogenic protein formulations
#513Pharmaceutical preparations and medicine capable of generating and/or containing thrombin
#514Dried blood factor composition trehalose
#515Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
#516Dried blood factor composition comprising trehalose
#517Factor IX: remolding and glycoconjugation of Factor IX
#518Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin
#519Factor VII polypeptide having factor VII:C activity
#520Reconstitution medium for protein and peptide formulations
#521Method of complexing a protein by the use of a dispersed system and proteins thereof